Cost-effectiveness analysis of endoscopic sinus surgery versus external approach for sinonasal inverted papilloma
Journal of Comparative Effectiveness Research · 2025
DOI: 10.57264/cer-2025-0109 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Comparative Effectiveness Research, 2025. Verfasst von Juan David Gutiérrez-Posso und 4 weiteren Autor:innen. Beteiligte Einrichtung: Otorhinolaryngology Department, Basurto University Hospital, OSI-Bilbao Basurto, Basque Country, Spain. Hauptthemen laut MEDLINE: Papilloma, Inverted, Endoscopy, Paranasal Sinus Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
Sinonasal inverted papilloma is a benign yet locally aggressive tumor with potential for recurrence. Surgical resection is the primary treatment, and both endoscopic sinus surgery (ESS) and external approaches are employed depending on tumor location and stage. While clinical outcomes of both techniques have been studied, their economic implications remain underexplored. Materials & methods: A retrospective cost-effectiveness analysis was conducted on 50 patients treated for histologically confirmed inverted papilloma between 1995 and 2018. Patients underwent either ESS or an external approach. Direct medical costs were calculated from hospital records, and effectiveness was measured by 5-year disease-free survival (DFS). Cost-minimization and cost-effectiveness analyses were performed, including subgroup evaluation by Krouse stage.
Results
The median total cost was significantly lower for the endoscopic group (€7567.23) compared with the external group (€11,456.40; p = 0.018). Endoscopic surgery resulted in an average savings of approximately €4000 per patient over a 5-year period. In localized disease tumors (Krouse I–II), ESS was both less costly and equally effective. Although the external approach showed a slightly higher DFS (77.2 vs 67.8%), the incremental cost-effectiveness ratio (ICER) was €40,837.13, suggesting limited cost-justification for this benefit.
Conclusion
Endoscopic surgery resulted in an average saving of approximately €4000 per patient over a 5-year period. While external approaches showed slightly better disease-free survival, the endoscopic technique proved significantly more cost-effective, offering a better balance between clinical outcomes and resource use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Otorhinolaryngology Department, Basurto University Hospital, OSI-Bilbao Basurto, Basque Country, Spain.
- BioBizkaia Health Research Institute, Barakaldo, Basque Country, Spain.
- School of Medicine, University of the Basque Country, Bilbao, Spain.
- Radiology Department, Cruces University Hospital, Barakaldo, Basque Country, Spain.
ORCID-Profile: Juan David Gutiérrez-Posso, Aitor Zabala-López-de-Maturana, Ana Maria Arango-Molina, Francisco Santaolalla-Montoya, Francisco Javier Santaolalla-Sanchez
Zitieren
APA
Gutiérrez-Posso, J. D., Zabala-López-de-Maturana, A., Arango-Molina, A. M., Santaolalla-Montoya, F., & Santaolalla-Sanchez, F. J. (2025). Cost-effectiveness analysis of endoscopic sinus surgery versus external approach for sinonasal inverted papilloma. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2025-0109
Vancouver
Gutiérrez-Posso JD, Zabala-López-de-Maturana A, Arango-Molina AM, Santaolalla-Montoya F, Santaolalla-Sanchez FJ. Cost-effectiveness analysis of endoscopic sinus surgery versus external approach for sinonasal inverted papilloma. Journal of Comparative Effectiveness Research. 2025. doi:10.57264/cer-2025-0109
BibTeX
@article{GutirrezPosso2025,
author = {Gutiérrez-Posso, Juan David and Zabala-López-de-Maturana, Aitor and Arango-Molina, Ana Maria and Santaolalla-Montoya, Francisco and Santaolalla-Sanchez, Francisco Javier},
title = {Cost-effectiveness analysis of endoscopic sinus surgery versus external approach for sinonasal inverted papilloma},
journal = {Journal of Comparative Effectiveness Research},
year = {2025},
doi = {10.57264/cer-2025-0109}
}
EUVIMED